Design Reviews

Design reviews represent the most critical quality control in medical device development. Done well, and they will expose fatal flaws that save time and money to fix. Done poorly, and they will become theatrical performances, where teams present polished narratives while fundamental problems remain undetected beneath the surface. The difference between an effective and ineffective design review isn't about how many people attend or how impressive the presentation looks. It's about whether the right expertise examines the right evidence at the right moment to answer the hardest questions, and with honesty: Regulatory approval, patient safety, and commercial viability all hinge on this distinction.

Most early-stage MedTech companies will approach design reviews as bureaucratic checkpoints rather than rigorous technical interrogations. They schedule reviews because regulations require them, not because they genuinely want to stress-test assumptions. They invite ‘friendly’ audiences predisposed to approval, rather than diverse experts equipped to identify weaknesses. They present conclusions rather than exposing uncertainties.

This approach doesn't fail immediately. It fails later, often expensively and irreversibly. The design flaws that courteous reviews miss will become the regulatory objections that delay approval, the quality failures that trigger recalls, and the liability exposures that destroy companies.

Breaking down the silos

Engineering teams naturally dominate early design reviews. They understand technical challenges, prototype iterations, and performance data. Their expertise proves essential but insufficient.

Medical device development requires simultaneous optimisation across multiple constraints. Technical performance matters, as does regulatory classification, reimbursement viability, manufacturing scalability, supply chain stability, and clinical workflow integration. These considerations will interact dynamically throughout development.

You need regulatory specialists to identify classification implications early: Reimbursement experts to flag coverage gaps before design freeze, quality engineers to spot manufacturing challenges during prototyping, and clinical advisors to confirm workflow integration throughout development. When these perspectives arrive late, they trigger redesigns that diverse review teams could have prevented from the start.

_{Dr Patrick Griss, Microsystems Technology Professor. Royal Institute of Technology, Stockholm.}

So, try to structure your design review team to represent every critical constraint. Include regulatory affairs professionals who understand classification nuances and standard requirements, invite reimbursement specialists who know coverage policies and health economics, and engage quality engineers focused on manufacturability and supplier management. This kind of diversity will transform your design reviews from a validation exercise into a genuine stress test.

Deep FMEA integration

Risk management shouldn't run parallel to design reviews. It should drive them. Every design decision will create, eliminate, or modify failure modes. Design reviews need to explicitly evaluate how proposed changes affect the risk profile. Shallow FMEA integration treats risk analysis as separate documentation that gets referenced briefly during reviews. Deep integration makes risk the primary lens through which design changes get evaluated. When engineers propose material substitutions, the review questions which failure modes this creates or eliminate. When features get added, the discussion focuses on new hazards introduced. When verification testing reveals unexpected behaviours, the review assesses risk management implications.

Try to track FMEA changes systematically through design iterations. Your design review documentation should show which risks existed at the previous review, which design changes occurred since then, how those changes affected the risk profile, and what new mitigation measures were implemented. This explicit linkage will demonstrate design control and your approach to risk management integration. Make sure to ask the questions that ensure risk management remains rigorous, rather than just checkbox compliance.

Maintaining traceability chains

Design reviews need to verify that clear chains of evidence connect user needs through design inputs, design outputs, verification testing, and validation activities. Broken traceability indicates loss of design control and triggers regulatory concerns.

Present your traceability matrix as a central review artefact. Walk through specific examples showing how clinical needs are translated into design requirements, how those requirements drive your design decisions, and how validation activities will prove clinical effectiveness. This demonstration proves systematic development rather than ad hoc problem-solving.

Regulators scrutinise design review records intensely to reveal whether companies maintain design control or just document it retrospectively. Strong reviews show teams actively check traceability, identify gaps, and then correct them. Weak reviews present polished narratives without evidence of critical examination. The difference becomes obvious during regulatory assessment and determines approval timelines.

_{Professor Cathal O'Connell, Director of Medical Device Innovation at Trinity College Dublin}

Confronting supplier risks early

While complex devices depend on purchased components to meet specifications, critical functionality often relies on supplier capabilities and quality systems. Many design reviews treat suppliers as external dependencies rather than integral design control elements. Supplier surprises emerge when critical components fail validation testing late in development. Try to address supplier risks explicitly during design reviews, ask which components are critical to safety or performance, and check whether supplier quality systems have been audited. These types of questions will expose supplier vulnerabilities before they become yours.

It’s important to include supplier validation data in review packages. Show the evidence that purchased components meet specifications consistently. Done this way, you can present supplier audit findings and quality agreements while demonstrating contingency planning for supply chain disruptions. This documentation will prove you've managed supplier risks in a systematic manner.

Capturing clinical reality continuously

Any user input that arrives after a design freeze will mean expensive redesign iterations. Features that seemed brilliant in engineering discussions prove unusable in clinical environments. Late user input only reflects inadequate engagement throughout development. It’s important to integrate clinical observation and feedback into every design review and present actual user testing data. Try to show procedure, shadowing findings and workflow analysis. Demonstrate how design decisions responded to clinical input (rather than preceded it).

Clinical advisors attending reviews should represent diverse user populations and use environments. A single enthusiastic early adopter will provide valuable input, but a limited perspective. Include conservative users resistant to change. Represent different clinical specialities, practice settings, and experience levels. This diversity will expose usability challenges that homogeneous user groups will miss.

Structuring for compliance

ISO 13485 and FDA design controls specify design review requirements explicitly. Reviews must occur at appropriate stages, involve qualified personnel representing all functions concerned with the design stage being reviewed, and maintain documented results, including identification of problems and required actions.

Structure your reviews around these regulatory frameworks rather than inventing custom approaches. This kind of compliance-focused structure will ensure reviews satisfy regulatory requirements while serving genuine technical purposes.

The design review workshop

Design reviews represent your best opportunity to find problems before patients do. With the VP Med Ventures design review workshop, you can structure them to surface weaknesses rather than validate strengths, include diverse expertise representing every critical constraint, and integrate risk management deeply rather than superficially. By maintaining rigorous traceability throughout and addressing supplier risks proactively, you can engage clinical reality continuously. The uncomfortable questions asked during reviews prevent the catastrophic failures discovered during clinical use. That's not bureaucracy. That's how medical device companies earn and maintain the trust that patient safety demands.

Waypoint checklist

Your design review is all about avoiding:

• Siloed reviews, which exclude regulatory/reimbursement teams
• Shallow FMEA, where risks aren’t always tied to design changes
• Broken traceability with no clear user need means you need to test the evidence chain
• Supplier surprises where critical parts fail validation late
• Late user input where clinician pain points are discovered post-design freeze